Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BrainDos semaglutide
- Development stage
- Preclinical
- Lead developer
- MetP Pharma
- Modality
- Peptides
- Administration
- Intranasal
01
Overview
BrainDos semaglutide is a preclinical intranasal, brain-targeted formulation of semaglutide being developed by Mattern Pharma using its proprietary BrainDos drug-delivery platform. The product is a peptide GLP-1 receptor agonist formulated in an oil-based intranasal system designed to bypass the blood-brain barrier, increase central nervous system exposure, and reduce systemic exposure relative to conventional delivery. Reported platform details indicate a thixotropic oleogel formulation with mucoadhesive nasal retention properties, intended primarily for obesity and related brain-targeted GLP-1 therapy, with potential broader relevance to disorders involving chronic brain inflammation.
- Brand names
- BrainDos
- Other names
- intranasal semaglutideBrainDos intranasal semaglutideSemaglutide
02
Targets
Beyond the preview
Go deeper on BrainDos semaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BrainDos semaglutide.